Business Wire

TX-ABS

20.7.2020 17:02:10 CEST | Business Wire | Press release

Share
ABS Takes Smart Class Services Mobile

ABS today launches a unique suite of fleet management and vessel compliance services powered by smart functionality and advanced analytics which, in an industry first, will also be available through the new ABS App .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200720005501/en/

Designed to anticipate client needs and provide intuitive, informed decision support, the smart functionality is an enhancement to the ABS MyFreedom™ client portal and can be accessed through a mobile app or text. The portal and the industry’s most user-friendly digital tools simplify access to operational, technical and compliance fleet intelligence and all ABS Class services to manage the operating health and performance of fleets.

New industry-leading smart functionality launched today includes:

  • The ABS Smart Scheduler™ , which leverages real-time AIS data to maintain fleet compliance and is the industry’s only mobile survey booking tool enabling any survey, including remote surveys, to be scheduled in less than a minute anytime, anywhere – even when there is no internet access. It tracks survey status for all vessels in a fleet and then issues alerts when surveys are due.
  • Custom Checklist , which brings together port state data from all ABS-classed vessels to provide a port-specific checklist for crew and fleet managers prior to arrival at any port.
  • Fee Estimator , which provides a comparison of estimated survey fees across multiple ports.
  • Port State Control Risk , which provides customized port state control analytics by vessel or fleet. It allows clients to view their destination’s top deficiency items and the client vessel’s matching findings from ABS class records, along with a vessel risk rating based on compliance health status.
  • International Safety Management (ISM) Findings , customized to individual vessel performance, which allows clients to view the destination port’s top ISM related deficiency items against their vessel’s matching findings from ABS class records.
  • Port-Specific External Specialists , which provides one-touch direct client connections for upcoming surveys.

“Leveraging unprecedented access to data, we are delivering truly smart functionality that learns from the user and, with experience over time, anticipates future requirements, making it even easier to work with ABS,” said Christopher J. Wiernicki, ABS Chairman, President and CEO. “These are just the first of many enhancements and increased smart functionality that ABS will continue to deliver through the MyFreedom client portal. The portal brings together all of our clients’ Class needs digitally for a complete overview, so now it all clicks. Centralized and connected, it streamlines interactions with ABS, making our client experience straightforward and insightful.”

Offering enhanced risk management, compliance and operational efficiency through better informed decision making, MyFreedom delivers total fleet oversight, real-time survey status, smart scheduling, remote survey options, including annual surveys with mobile capture and collaboration, simplified access to compliance data and timely fleet certification renewals.

Visit our website for more information.

The ABS App is now available from the Apple App Store and Google Play .

▬▬

About ABS
ABS, a leading global provider of classification and technical advisory services to the marine and offshore industries, is committed to setting standards for safety and excellence in design and construction. Focused on safe and practical application of advanced technologies and digital solutions, ABS works with industry and clients to develop accurate and cost-effective compliance, optimized performance and operational efficiency for marine and offshore assets.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye